Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The "Empty Capsules Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global empty capsules market reached a value of US$ 2.61 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 4.14 Billion by 2027 ...
read more
The omega-3 supplements market was valued at $28,817B in 2021 and is projected to reach $50,845B by 2028; it is expected to grow at a CAGR of 8.4% during 2021-2028.
read more
Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare.
read more
Adults with severe alopecia areata (AA) who took OLUMIANT® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to OLUMIANT 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company) and Incyte announced at the American Academy of Dermatology (AAD) Annual Meeting.
read more
The global vegetarian softgel capsules market was valued at $527.28M in 2020 and is projected to reach $824.39M by 2030, registering a CAGR of 4.6% from 2021 to 2030.
read more
Exelixis, Inc.announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid ...
read more
NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
read more
Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies and Siemens' global leadership in automation and digitization is expected to lead to innovative and ...
read more
Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at $53.3B in 2021, is projected to reach a revised size of US$80.2 Billion by 2026, growing at a CAGR of 8.1% over the analysis period.
read more
AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, announced further positive results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-...
read more
The global D-Mannose is slated to expand at a CAGR of 4.2 percent and reach a valuation of close to US$ 5.5 B by 2031, according to a report by Persistence Market Research.
read more
Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, Inc. in the U.S. market.
read more
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Analgesics - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
read more
Coronavirus (COVID-19) current therapy market segmentation is done by drug type into antiviral, monoclonal antibodies, corticosteroid, supplements, antimalarial, interferons and interleukin inhibitors, other anti-infective drugs and others. The antiviral was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug ...
read more
The world pharmaceutical market was worth an estimated $1.2 trillion at ex-factory prices in 2020. It is one of the top performing industries globally.
read more